Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer Patients with MCRC were randomly ...

Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia Medical providers should screen by testing ...

Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada. This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary ...

Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human ...

*Safety data percentages are calculated from the safety population (n=338 for durvalumab + GemCis and n=342 for placebo + GemCis). This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal ...

Efforts to reduce global cancer disparities begin with an understanding of geographic patterns in cancer incidence, mortality, and prevalence. Using the GLOBOCAN (2002) and Cancer Incidence in Five ...

Over the past decade, significant advances have been achieved in the diagnostic testing, treatment, and prognosis of advanced non–small-cell lung cancer (NSCLC). One of the most significant ...

Biological characteristics and prognostic value of Tfh-like cells in the tumor tissue of breast cancer. This is an ASCO Meeting Abstract from the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.

Improving detection of higher-risk or locally advanced disease features in stage I and II renal cell carcinoma. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This ...

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject ...

This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.

Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer The following represents disclosure information ...